Funded Biotechnology Startups in Minneapolis
The 11 most recent biotechnology funding rounds in Minneapolis span from September 2022 through August 2025, with disclosed amounts ranging from $10K (Evia…
The 11 most recent biotechnology funding rounds in Minneapolis span from September 2022 through August 2025, with disclosed amounts ranging from $10K (Evia Bio) to $3.5B (Medtronic's Post-IPO Debt raise). The two largest rounds anchor opposite ends of the timeline: Medtronic's debt financing in September 2022 and ALT5 Sigma Corp's $1.5B Series Unknown close in August 2025. Mid-market activity appears in DiaMedica's $38M round (June 2023) and Marker Therapeutics' $25M raise (December 2022).
Three rounds closed in 2025 — ALT5 Sigma Corp, FOXO Technologies ($2M), and Luminary Therapeutics ($6M) — all carrying Series Unknown designations. Of the 11 rounds shown, only Vergent Bioscience (Series B, $22M, October 2022) and Neurotype Inc. (Seed, $330K, July 2023) have named institutional stages; the remaining rounds are classified as Series Unknown or Post-IPO Debt, which limits stage-level filtering but reflects standard reporting gaps at both the pre-seed and late-growth ends of the market.
Most recent rounds
11 shownRelated listings
Frequently asked
What are the largest recent funding rounds among Minneapolis biotech companies in this data?
Medtronic's Post-IPO Debt round of $3.5B (September 2022) and ALT5 Sigma Corp's $1.5B raise (August 2025) are the two largest disclosed amounts. The next tier includes DiaMedica at $38M (June 2023) and Marker Therapeutics at $25M (December 2022).
Which Minneapolis biotech companies raised funding most recently?
ALT5 Sigma Corp closed a $1.5B Series Unknown round on August 11, 2025, followed by FOXO Technologies ($2M) in June 2025 and Luminary Therapeutics ($6M) in March 2025. All three carry Series Unknown designations.
What round stages appear in the Minneapolis biotech funding data shown here?
Most rounds are classified as Series Unknown. Vergent Bioscience is the only Series B company shown ($22M, October 2022), Neurotype Inc. is the sole Seed-stage entry ($330K, July 2023), and Medtronic's round is Post-IPO Debt.
How wide is the deal-size range across the Minneapolis biotech rounds listed?
Disclosed amounts run from $10K (Evia Bio, December 2022) and $50K (Nuvaira, May 2024) at the low end to $3.5B (Medtronic) and $1.5B (ALT5 Sigma Corp) at the top, reflecting a market that mixes very early-stage companies with a large public incumbent.
Which Minneapolis biotech companies raised mid-market rounds in the $1M–$50M range?
Six of the 11 rounds fall in that band: DiaMedica ($38M), Marker Therapeutics ($25M), Vergent Bioscience ($22M), Luminary Therapeutics ($6M), Humanetics Corporation ($5M), and FOXO Technologies ($2M), spanning October 2022 through June 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.